Clinical Trials Using Gemcitabine

Clinical trials are research studies that involve people. The clinical trials on this list are studying Gemcitabine. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 112

  • Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

    This is an open-label, multinational, parallel 2-arm, randomized Phase 3 study evaluating the efficacy and safety of futibatinib versus gemcitabine-cisplatin chemotherapy as first-line treatment of patients with advanced, metastatic, or recurrent unresectable iCCA harboring FGFR2 gene rearrangements
    Location: 3 locations

  • A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

    The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, as well as Nivolumab / Ipilimumab for selected advanced solid tumors.
    Location: 3 locations

  • Nab-Paclitaxel, Gemcitabine, and Hypofractionated Ablative Proton Therapy in Treating Patients with Locally Advanced Pancreatic Cancer

    This phase I trial studies the side effects and best dose of nab-paclitaxel and gemcitabine when given together with hypofractionated ablative proton beam radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced). Chemotherapy drugs, such as nab-paclitaxel and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving nab-paclitaxel, gemcitabine, and proton beam radiation therapy may work better in treating patients with pancreatic cancer.
    Location: 3 locations

  • A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

    This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in patients with metastatic non-small cell lung cancer (NSCLC). Two cohorts will be enrolled in parallel in this study: the first-line (1L) cohort will consist of patients who have not received any systemic therapy for their disease and the second-line (2L) cohort will consist of patients who progressed during or after receiving a platinum-containing regimen and a PD-L1 / PD-1 checkpoint inhibitor treatment. In each cohort, eligible patients will be assigned to one of several treatment arms.
    Location: 4 locations

  • A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

    This is a phase 2 / 3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.
    Location: 4 locations

  • Paediatric Hepatic International Tumour Trial

    The PHITT trial is an over-arching study for patients with Hepatoblastoma (HB) and Hepatocellular Carcinoma (HCC). This trial will use a risk-adapted approach to the treatment of children diagnosed with HB. Children with HCC will be included as a separate cohort.
    Location: 3 locations

  • Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma

    A phase 1b / 2, open-label, multinational, interventional trial to evaluate the safety, tolerability, PK, pharmacodynamics / biomarkers, immunogenicity, and preliminary efficacy of epcoritamab in combination with other standard of care (SOC) agents in subjects with B-NHL.
    Location: 2 locations

  • A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients

    This study combines canakinumab (ACZ885), a high-affinity human anti-interleukin-1β (IL-1β) monoclonal antibody (mAb), and spartalizumab (PDR001), a mAb directed against human Programmed Death-1 (PD-1), with the chemotherapy combination of gemcitabine and nab-paclitaxel. This study will confirm for this 4-drug combination the tolerable doses, the acceptable safety profile, and the dose to be used for a Phase II combination treatment regimen.
    Location: 2 locations

  • Gemcitabine, Bendamustine Hydrochloride, and Nivolumab in Treating Patients with Relapsed or Refractory Classic Hodgkin Lymphoma

    This phase I / II trial studies the side effects and best dose of gemcitabine, bendamustine hydrochloride, and nivolumab when given together and to see how well they work in treating patients with classic Hodgkin lymphoma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as gemcitabine and bendamustine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving gemcitabine, bendamustine hydrochloride, and nivolumab may work better in treating patients with classic Hodgkin lymphoma.
    Location: 2 locations

  • Talimogene Laherparepvec with Chemotherapy or Endocrine Therapy in Treating Patients with Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer

    This phase Ib trial studies the side effects and how well talimogene laherparepvec works when given together with chemotherapy or endocrine therapy in treating patients with breast cancer that does not express the human epidermal growth factor receptor 2 (HER2) protein and has spread to other places in the body (metastatic), cannot be removed by surgery (unresectable), or has come back (recurrent). Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may attack specific tumor cells and stop them from growing or kill them. Chemotherapy drugs, such as nab-paclitaxel, gemcitabine, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Estrogen can cause the growth of breast cancer cells. Drugs used as endocrine therapy, such as letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, may lessen the amount of estrogen made by the body or may stop the growth of tumor cells by blocking estrogen from connecting to the cancer cells. Giving talimogene laherparepvec with chemotherapy or endocrine therapy may work better in treating patients with HER2-negative breast cancer.
    Location: 2 locations

  • Carbon Ion or Conventional Photon Radiation Therapy and Chemotherapy in Treating Patients with Locally Advanced, Unresectable Pancreatic Cancer

    This phase III trial studies how well carbon ion radiation therapy works compared to conventional photon radiation therapy when giving together with chemotherapy in treating patients with pancreatic cancer that has spread from its original site of growth to nearby tissues or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable). Carbon ion radiation therapy uses charged carbon particles to kill tumor cells and shrink tumors. Conventional photon radiation therapy, such as intensity-modulated radiation therapy is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. This type of radiation therapy reduces the damage to healthy tissue near the tumor. Drugs used in chemotherapy, such as gemcitabine, nab-paclitaxel, capecitabine, fluorouracil, irinotecan, leucovorin and oxaliplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Given carbon ion radiation therapy with chemotherapy may kill more tumor cells in patients with pancreatic cancer compared to conventional photon radiation therapy and chemotherapy.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts

    The purpose of this study is to evaluate the efficacy and safety of chemotherapeutic pancreatic cyst ablation using ethanol lavage followed by the infusion of a dual-agent chemotherapeutic cocktail (paclitaxel + gemcitabine) compared with alcohol-free saline lavage followed by infusion of the same dual-agent chemotherapeutic cocktail (paclitaxel + gemcitabine) for the ablation of pancreatic cystic neoplasms using endoscopic ultrasound guided fine needle infusion (EUS-FNI) for agent delivery.
    Location: 2 locations

  • A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

    This study will evaluate the surgical safety and feasibility of atezolizumab plus tiragolumab alone or in combination with platinum-based chemotherapy as neoadjuvant treatment for participants with previously untreated locally advanced non-small cell lung cancer (NSCLC). The study will also evaluate the efficacy, pharmacokinetics, immunogenicity, and safety of atezolizumab plus tiragolumab alone or in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by adjuvant atezolizumab plus tiragolumab or adjuvant platinum-based chemotherapy.
    Location: 2 locations

  • First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

    This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-01-097 in patients with advanced solid tumors.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Cytoreductive Surgery with Gemcitabine Followed by Dacarbazine for the Treatment of Locally Recurrent Uterine Leiomyosarcoma

    This phase II trial studies the effects of giving a dose of heated chemotherapy (gemcitabine) in the abdomen immediately after cytoreductive surgery in patients with uterine leiomyosarcoma that has come back (locally recurrent). Cytoreductive surgery is a surgical procedure that aims to remove all visible tumors from the abdominal cavity. Heated chemotherapy is a treatment that uses heated chemotherapy inside the abdomen at the time of surgery to try to eliminate any remaining cancer cells and decrease chances of disease recurrence. Chemotherapy drugs, such as gemcitabine and dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving a dose of heated chemotherapy in the abdomen immediately after cytoreductive surgery may lower the risk of the cancer coming back in the future.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

    This study will evaluate the efficacy and safety of atezolizumab with bevacizumab in combination with cisplatin and gemcitabine(CisGem), compared with atezolizumab in combination with CisGem, in participants with advanced biliary tract cancer (BTC) who have not received prior systemic therapy. Treatment will consist of a chemotherapy combination phase followed by a cancer immunotherapy (CIT) / placebo phase.
    Location: 2 locations

  • Testing the Addition of an Anti-cancer Drug, BAY 1895344 ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

    This phase I trial identifies the best dose, possible benefits and / or side effects of gemcitabine in combination with BAY 1895344 in treating patients with pancreatic, ovarian, and other solid tumors that have spread to other places in the body (advanced). Gemcitabine is a chemotherapy drug that blocks the cell from making DNA and may kill tumor cells. BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine and BAY 1895344 in combination may shrink or stabilize cancer.
    Location: Dana-Farber Cancer Institute, Boston, Massachusetts

  • Immunotherapy (Cemiplimab and Motixafortide) and Chemotherapy (Gemcitabine and Nab-Paclitaxel) for the Treatment of Stage IV Pancreatic Cancer, the Chemo4METPANC Trial

    This phase II trial investigates how well immunotherapy (cemiplimab and motixafortide) and chemotherapy (gemcitabine and nab-paclitaxel) work in treating patients with stage IV pancreatic cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Motixafortide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving immunotherapy (cemiplimab and motixafortide) and chemotherapy (gemcitabine and nab-paclitaxel) may decrease tumor size and prolong life in patients with pancreatic cancer.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • Pancreatic Adenocarcinoma Signature Stratification for Treatment

    This is a randomized multicentre phase II trial with a large translational component. The trial will evaluate the two standard chemotherapy regimens: modified folfirinox (mFFX) and gemcitabine / nab-paclitaxel (GA), in patients with untreated metastatic pancreatic ductal adenocarcinoma. Integrated into this phase II trial are a number of laboratory components including molecular profiling, patient derived organoid establishment, and drug testing sensitivity and other biomarkers.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Pulsed Low-Dose-Rate Radiation for the Treatment of Pancreatic Cancer

    This phase I trial investigates the side effects and best dose of pulsed low-dose-rate radiation (PLDR) in treating patients with pancreatic cancer. During PLDR, radiation delivered is broken into pulses over a relatively longer period of time. Undergoing PLDR may create a more favorable environment for tumor shrinkage with fewer side effects and less damage to surrounding vital organs compared to conventional radiation therapy. It also may make surgery a more likely option in patients who are not otherwise good candidates for surgery to remove the tumor.
    Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania

  • A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed / Refractory Diffuse Large B-cell Lymphoma

    The purpose of this Phase 2 / 3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR-T) therapy. The Phase 2 portion of the study will assess the two doses of selinexor (40 milligram [mg] or 60 mg) in combination with R-GDP, for up to 6 cycles (21-day per cycle), followed by 60 mg selinexor single agent continuous therapy for those who have reached a partial or complete response. The Phase 3 portion of the study will evaluate the selected dose of SR-GDP (identified in Phase 2) versus standard R-GDP + matching placebo, for up to 6 cycles (21-day per cycle), followed by placebo or 60 mg selinexor single agent continuous therapy for those who have reached partial or complete response.
    Location: University of Maryland / Greenebaum Cancer Center, Baltimore, Maryland

  • AGEN1884 and AGEN2034 in Combination with Cisplatin and Gemcitabine for the Treatment of Muscle-invasive Bladder Cancer before Radical Cystectomy

    This phase II trial investigates how well AGEN1884 and AGEN2034 work in combination with cisplatin and gemcitabine in treating patients with muscle-invasive bladder cancer before surgery that removes all of the bladder as well as nearby tissues and organs (radical cystectomy). AGEN1884 (a CTLA-4 blocking agent) and AGEN2034 (a PD-1 blocking agent) are a class of drugs called immune checkpoint inhibitors that may help the body's immune system attack the cancer and interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Standard of care treatment of muscle-invasive bladder cancer is chemotherapy followed by surgery and a cystectomy. Adding AGEN1884 and AGEN2034 to this standard treatment may improve the rate of the bladder cancer coming back.
    Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas

  • Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.
    Location: University of California San Diego, San Diego, California

  • Study of SRF617 in Patients With Advanced Solid Tumors

    A Phase 1, first-in-human, SRF617 monotherapy and combination therapy, dose escalation, safety, and tumor biopsy expansion study of SRF617, an antibody that inhibits CD39 activity, in patients with advanced solid tumors. Inhibition of CD39 activity may improve the ability to mount an immune response against tumor cells.
    Location: 2 locations

  • Hepatic Arterial Infusion Using Codman Catheter / Synchromed Pump for the Treatment of Unresectable Colorectal Cancer Liver Metastases or Unresectable Intrahepatic Cholangiocarcinoma

    This phase I trial studies the side effects of hepatic arterial infusion (HAI) using the Codman catheter / Synchromed pump in treating patients with colorectal cancer that has spread to the liver (metastases) and cannot be removed by surgery (unresectable) or unresectable intrahepatic cholangiocarcinoma. HAI is a procedure in which chemotherapy drugs are directly delivered to the liver through a pump that is surgically implanted into the liver. This approach can produce higher local concentrations of the infused drug with few systemic side effects. The manufacturer of the main pump device used for HAI terminated production in April 2018. Thus, alternate means of employing HAI need to be devised in order to continue offering this therapy. This trial may help researchers learn about the safety of HAI using a similar pump, the Synchromed II, combined with a Codman vascular catheter.
    Location: University of Kentucky / Markey Cancer Center, Lexington, Kentucky